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SUMMARY
Objective: To determine the compliance of quality care
indicators (GESIDA) for adult patients living with HIV in-
fection in PSITAR cohort.
Methods: Multi-center, prospective observational study. All
adult naive patients, that began treatment during 2011 be-
longing to the PSITAR cohort, were selected. We recorded
demographic data, virological parameters at baseline and
48 weeks of treatment and pharmacotherapy variables. The
selected indicators were: The compliance of initial antiretro-
viral therapy with the Spanish national treatment guidelines
(GESIDA) for treatment-naive HIV-infected patient (95%),
undetectable viral load at 48 weeks (80%), treatment initia-
tion with Abacavir without screening for HLA-B*5701 (0%),
treatment modifications within the first year (<30%), adhe-
rence treatment measure (95%), study of resistance in the
virologic failure (90%) and average expenditure per patient
in the first treatment (GESIDA median).
Results: In total 108 HIV+ naive patients were included,
83.3% men. The median age was 40.5 years (21-75). The
most frequent combination was tenofovir-emtricitabine-
efavirenz with 61.0%. 28 patients (29.7%) modified their
treatment during the first year. Focusing on indicators
compliance, starting of treatment with a recommended
regimen had 95.4% of compliance, undetectable viral
load indicator 74.1%, treatment initiation without Aba-
cavir test 0%, treatment modifications within the first year
25.9%, adherence treatment measure 86.3%, study of
resistance in the virologic failure 80% and average expen-
diture per patient was 8,846 euros.
Conclusion: Quality care follow up indicators were fulfi-
lled in their vast majority. The worst accomplished indi-
cators such as undetectable viral load at 48 weeks,
evaluation of adherence and study of resistance must be
study to examine the possible improvement points.
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INTRODUCTION
Highly activity antiretroviral therapy (HAART) has subs-
tantially reduced morbidity and mortality in patients in-
fected with human immunodeficiency virus (HIV) since
its introduction in 1996. This has changed the natural his-
tory of disease1,2. Over the past few years, drug develop-
ment has evolved to achieve, in most cases, a partial
restoration of the immune system3 and an approach to
the life expectancy of the general population4.
Both treatment and monitoring of HIV-infected pa-
tients are gradually becoming more complex. This and
the fact that, HIV disease is considered as a chronic dise-
ase, leads to an increased demand for standardize the
care for these patients5. In order to determine the quality
of clinical practice and to implement the appropriate im-
provements, in 2010, GESIDA (Spanish Study Group on
AIDS) quality care indicators for adult patients living with
HIV infection were published6.
Of these, drug therapy management indicators play
a key role, as evidenced by the fact that four of these in-
dicators are included among the most relevant indicators
and eight among indicators of basic accreditation.
In addition, pharmacotherapy follow-up is a basic pi-
llar of achieving the goals of pharmacotherapy patients.
On the other hand, in general, hospital pharmacist role
has changed in our working frame. Simple concept of
pharmacist as “drugs dispenser” has been replaced by
more active and dynamic role. Pharmacist has become
co-responsible, with the other members of the multidis-
ciplinary team, for clinical outcomes of drug prescribed
to each patient. All this shows the importance of phar-
macist dedicated to VIH patient’s health care and they are
a key element of therapy management and rational drug
use.
In order to facilitate pharmacotherapy follow-up and
to obtain useful outcomes indicators such as drug effec-
tiveness and safety, PSITAR cohort was developed with its
specific registry tool.
PSITAR is a prospective HIV naive patient’s cohort. This
cohort collects information from patients over 18 years
of age belonging to seven hospitals in Andalusia. Patients
were included in PSITAR cohort from 2011 to the present.
This new tool is meant to solve one of the main pro-
blems faced by health professionals: dispensing hetero-
geneous software and they are not geared towards drug
pharmacotherapy management patients. 
This online platform allows easily introducing and ex-
ploiting demographic, analytical and pharmacological
parameters of patients at baseline and it allows monito-
ring their development over time.
The aim of this study is to assess the compliance of
quality care indicators (GESIDA) for adult patients living
with HIV infection in PSITAR cohort.
METHODS
We performed a multi-center, prospective observational
study. All adult naive patients, that began treatment du-
ring 2011 and were treated in outpatient pharmacy hos-
pitals belonging to the PSITAR cohort, were selected.
Also, they must complete a full year of follow-up. Patients
participating in clinical trials or expanded access to anti-
retroviral drugs were excluded.
We recorded demographic data: Age at treatment initia-
tion and sex; Virological parameters at baseline and 48
weeks of treatment as CD4 cells (Cel/mL) count and viral
load (copies/mL) and pharmacotherapy variables: First
HAART regimen, primary antiretroviral resistance (before
treatment initiation), discontinuation in the first 48 weeks
of treatment and their causes based on Swiss HIV Cohort7.
The main reason for treatment modification was classified
as treatment failure, intolerance and/or toxic effects, the
patient’s choice, the physician’s decision, and other rea-
sons.
Finally, treatment adherence was recorded by SMAQ
questionnaire and recording drug dispensations.
The costs of each regimen were calculated from the
laboratory sales price plus 4%. The costs of each HAART
were calculated from drug price they include. In case
there are combinations, the price would be based on
price of the combo. Prices were obtained from consensus
GESIDA/National AIDS Plan 20118.
Quality care indicators (GESIDA) for adult patients li-
ving with HIV infection are described in the document,
with the same name, published in 20116. 
RESUMEN
Objetivos: Determinar el cumplimiento
de los indicadores de calidad de la acti-
vidad asistencial GESIDA en la cohorte
de pacientes VIH+ PSITAR.
Método: Estudio multicéntrico prospec-
tivo. Se seleccionaron aquellos pacientes
VIH naive adulto que iniciaron trata-
miento en 2011. Se recogieron variables
demográficas, analíticas y farmacotera-
péuticas. Los indicadores seleccionados
fueron: adecuación de las pautas inicia-
les de TAR a las guías españolas (95%),
carga viral indetectable al año de trata-
miento (80%), tratamiento con abaca-
vir sin HLA-B*5701 previo (0%), cam-
bios de tratamiento durante el primer
año (<30%), registro de la adherencia
al tratamiento (95%), estudio de resis-
tencias en el fracaso virológico (90%) y
gasto medio por paciente en primer tra-
tamiento (mediana GESIDA).
Resultados: Se incluyeron 108 pacien-
tes, de ellos el 83,3% hombres. La me-
diana de edad fue de 40,5 años
(21-75). La combinación de inicio
más frecuente fue emtricitabina-teno-
fovir-efavirenz (61%). El 95,4% de los
pacientes iniciaron con un tratamiento
considerado preferente. El 74,1% pre-
sentó carga viral plasmática indetecta-
ble a las 48 semanas. Ningún paciente
inicio tratamiento con abacavir sin la de-
terminación del HLA-B*5701. El 25,9%
discontinuó el TAR en el primer año, re-
gistrándose una valoración de la adhe-
rencia en el 86,3% de los casos. El
estudio de las resistencias en fallo viro-
lógico se realizó en el 80,0% de los pa-
cientes y el gasto medio fue de 8.846
euros.
Conclusiones: Los indicadores de ca-
lidad de la actividad asistencial se
cumplen ampliamente. La carga viral
plasmática indetectable, la valoración
de la adherencia y el estudio de resis-
tencia requieren de un mayor estudio
para detectar puntos de mejora.
Análisis del cumplimiento de los indicadores de calidad
de GESIDA en la cohorte de pacientes VIH+ PSITAR
Palabras clave: VIH, indicadores de calidad asistencial sanitaria, tratamiento farmacológico.
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In the final document, 66 indicators were included as
follows: Structural conditions, diagnosis and evaluation, fo-
llow-up and preventive interventions, follow-up of patients
under treatment, specific aspects in women, comorbidities,
hospitalization, mortality rates, training and research.
The indicators which were chosen belong to follow-up
of patients under treatment section. The following indica-
tors were selected:
The compliance of initial antiretroviral therapy (ART)
with the Spanish national treatment guidelines (GESIDA
Guidelines) for treatment-naive HIV-infected patient. The
guidelines’ recommendations for initiating antiretroviral
treatment are shown in table 1. Undetectable viral load
was defined as a viral load of <50 HIV-1 RNA copies/ml at
48 treatment weeks, treatment initiation with Abacavir
without screening for HLA-B*5701, treatment modifica-
tions within the first year, adherence treatment measure,
study of resistance in the virologic failure and average ex-
penditure per patient in the first treatment. Features of
each indicator are shown in table 2.
Statistical analysis
The main variables are taken from the data collection plat-
form PSITAR. The data have been introduced by the heads
of each hospital centre through review of dispensations in
the outpatient program and review of medical history. The
quantitative variables are expressed as median and inter-
quartile range and the qualitative values as percentages. All
statistical analyses were performed using SPSS v.20.0.
RESULTS
Baseline characteristics 
In total 108 HIV+ naive patients from seven hospitals were
included in the study, 83.3% of them were men. The me-
dian age was 40.5 years. At the time of initiation of therapy,
few patients, 24.1% had an advanced immune deficiency
(CD4 cells below 200/ml). The rest of baseline socio-de-
mographic and clinical characteristics are listed in table 3.
Pharmacotherapeutic treatment
Regarding the initial therapy, the most frequent combi-
nation in naive patients was tenofovir-emtricitabine with
efavirenz with 61.0% of the patients, followed by tenofo-
vir-emtricitabine with atazanavir/ritonavir 15.8%, tenofovir-
emtricitabine with darunavir/ritonavir 12.0% and another
combinations 11.2%.
Information on primary resistance was available in 73
patients; including three patients had primary drug resis-
tance: one patient developed resistance to protease-inhi-
bitor (PI) and two patients to Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTIs).
Of 108 individuals starting ART, 28 (29.7%) modified
their treatment during the first year. The most frequent
reasons for treatment modification were toxic effects
(60.7%), followed by a physician’s decision (14.3%), treat-
ment failure (17.8%) and other reasons (7.2%).
Finally, in relation to adherence to antiretroviral the-
rapy, 22.2% of the patients were non-adherent to one
year after treatment initiation.
Table 1
Guidelines’ recommendations for initiating anti-retroviral treatment, GESIDA 2011
3rd Drug Regimen Clinical randomized trials
Preferred
NNRTIs
TDF/FTC/EFV ECHO, THRIVE, STARTMRK,2NN,ACTG 5202, ASSERT, 934, MERIT,ACTG 5142
ABC/3TC + EFV* ACTG 5202, ASSERT, CNA30024
TDF/FTC + NVP* ARTEN, OCTANE II
PI/r
ABC/3TC + ATV/r* ACTG 5202
ABC/3TC + LPV/r * KLEAN, HEAT
TDF/FTC/ATV/r CASTLE, ACTG 5202, ARTEN
TDF/FTC/DRV/r ARTEMIS
TDF/FTC + LPV/r* ARTEMS, 730, CASTLE, GEMINI, OCTANE II, HEAT, ACTG 5142
NRTIs TDF/FTC + RAL STARMRK
Alternative
NRTIs
ddI+3TC+EFV GESIDA 3903
AZT/3TC+ EFV 934, CNA30024
PI/r
ABC/3TC + FPV/r KLEAN
TDF/FTC + SAQ/r GEMINI
Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de
la inmunodeficiencia humana (Actualización enero 2011).
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Quality care indicators
The most accomplished quality indicators were treatment
initiation with Abacavir without screening for HLA-B*5701
with 100% compliance (no patient) and the start of treat-
ment with a recommended regimen as GESIDA guidelines
with 95.4% compliance. Antiretroviral therapy disconti-
nuation in the first 12 months was above the reference
value with 25.9% of cases.
At the opposite end, quality indicators with poorer
outcomes were study of resistance in the virologic failure
with 80.0% compliance, not exceeding the minimum
value, as well as undetectable viral load indicator with
74.1%. Adherence recording didn’t reach the reference
value with 86.3% either.
Finally, focusing on cost, mean health expenditure per
patient per year was 8,846.0 euros (11,796$). This figure
is below the median of rates published in 2011 by GESIDA,
with a value of 9,403.8 euros (12,540$).
DISCUSSION
Our study shows that the compliance of drug therapy
management indicators (GESIDA) for adult patients living
with HIV infection in PSITAR cohort was elevated. 
Currently, there are no studies examining the com-
pliance of quality care indicators (GESIDA) for adult pa-
tients since its publication in 2010. There are studies that
scan the adherence to guidelines and one paper studies
these quality indicators in pediatric population. In this
Table 2
Indicators description
Quality care indicators (GESIDA) for adult patients living with HIV infection
Pharmacotherapeutic follow-up indicators
Indicators Dimension Formula Population Standard
Compliance of initial antire-
troviral therapy with the
Spanish national treatment
guidelines for treatment-
naive HIV-infected patient
EFFECTIVENESS
Number of adult naive patient
that began ART with preferred
regimens x 100 / Number of adult
naive patient that began ART
All adult naive patients that
began treatment. No clinical
trial patients
95%
Undetectable viral load
(<50 copies/ml) at 48
treatment weeks
EFFECTIVENESS
Number of patient that began ART
and reached undetectable viral
load at 48 week x 100 / Number
of patient that began ART
All adult naive patients that
began treatment 80%
Treatment initiation with
Abacavir without screening
for HLA-B*5701
SECURITY
Treatment initiation with Abacavir
without screening for HLA-B*5701
x 100 / Number of patient that
began ART
All patient that began ART with
Abacavir. Not included if they
had taken it before
0%
Treatment modifications
within the first year EFFECTIVENESS
Number of patient  that  made
treatment modifications within
the first year x 100 / Number of
patient that began ART
All adult naive patients that
began treatment. Not included
loss follow-up, clinical trial and
pregnancy
<30%
Adherence treatment
measure FOLLOW-UP
Number of patient with adherence
measure x 100 / Number of patient
that began ART
All adult naive patients that
began treatment 95%
Study of resistance in 
the virologic failure EFFECTIVENESS
Number of patient with virologic
failure and study of resistance 
100/ Number of patient with
virologic failure
Patient with virologic failure.
Not included patients with viral
load greater than 1000 cop/mL
90%
Average expenditure per
patient in the first treat-
ment
EFICIENCY
Total annual expenditure in  that
began ART during 12-24 months
before / Number of patient  that
began ART and reached undetec-
table viral load at 48 week
All adult naive patients that
began treatment in 12-24
months before
GESIDA
median
Indicadores de calidad asistencial GESIDA para la atención de personas infectadas por el VIH/sida. Enferm Infecc Microbiol Clin.
2010.28(Supl5);6-88.
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study, quality indicators were adapted to pediatrics pa-
tients9. All indicators in the follow-up section exceeded
standards values less undetectable viral load. In spite of
having this document, it is necessary to use the consensus
GESIDA/National AIDS Plan 20118 to analyze our results.
Among the indicators with better compliance profile
are the following: treatment initiation with Abacavir wi-
thout screening for HLA-B*5701, treatment initiation with
a recommended regimen as GESIDA guidelines and anti-
retroviral therapy discontinuation in the first 12 months
indicator. The cost per patient per year of treatment is less
than the value proposed in the indicator description.
By contrast, the worst accomplished quality indicators
are the percentage of patients with undetectable viral
load, study of resistance in the virologic failure and adhe-
rence assessment.
In relation to HLA-B*5701 determination, this proce-
dure is routinely done and has been incorporated into
daily clinical practice since 2002, when an association
between a diagnosis of hypersensitivity reaction to aba-
cavir and carriage of the major histocompatibility com-
plex class I allele HLA-B*5701 was reported independently
by two research group10,11.
In reference to the compliance with clinical practice
guidelines for antiretroviral treatment indicator, we knew
that most combinations of current drugs achieve unde-
tectable viral load in 70.0% of cases at 48 weeks12. Drugs
combinations supported by the largest number of clinical
trials with optimal efficiency and durability, acceptable to-
lerance and ease of use are considered "Preferred regi-
mens"5.
We found that the choice of initial antiretroviral regi-
men was appropriate in most cases: 95.4% of patients
started treatment that was considered recommended by
GESIDA guidelines. This is consistent with a study in the
Spanish Asociación Médica Vach de Estudios Multicéntri-
cos (VACH) cohort in the years 2004-2006, which found
that initial treatment regimens were compliant with the
guidelines in 95% of cases13.
Suarez-Garcia et al. study14, carried out in Spanish co-
hort CORIS, shows a lower adequacy with 91.5% com-
pliance including preferred and alternative regimens. This
data may be because in this study patients have been in-
cluded since 2004. Since then, knowledge about different
antiretroviral treatments has strongly developed and most
complete guidelines have been elaborated and have been
used by many health professionals.
Studies from the USA have found lower percentages
of compliance15-17. For example, the Wandeler et al. study
which compared initial antiretroviral regimens with Ame-
rican clinical practice guidelines, showed a compliance
rate of 73.018. These differences across studies can partly
be attributed to different populations and health care
systems, use of different guidelines and general differen-
ces in the experience of caring for HIV-infected patients.
At last, several studies have focused on the analysis of
discontinuations of antiretroviral therapy. Initial ART can
be maintained over many years. Discontinuation of ART
during first year due to its toxicity can have a negative
impact on adherence or virological response. Elzi et al.7
in their study collected all treatment modifications in
Swiss cohort of HIV patients between 2005 and 2008
with a percentage of discontinuations during the first year
of 41.5%.
The broad availability of new drugs with the possibility
of once-daily regimens may have triggered treatment
modification, as suggested by the high proportion of pa-
tients switched to another antiretroviral regimen in this
study19-21.
Recently, a work has been published by The Antire-
troviral Therapy Cohort Collaboration (ART-CC)22 where
the percentage of treatment discontinuation and its
causes has been analyzed in 18 European and American
cohorts between 2002 and 2009. Their results were dis-
continuation percentages close to 50% supporting this
idea.
Cost per patient per year of treatment value was
below the median cost of the preferred GESIDA regimens8
and at the lower limit of data obtained in the Blasco A et
al. study which has been evaluated the costs and the cost
effectiveness of initiating treatment following GESIDA gui-
delines in different situations in 201123.
Table 3
Baseline characteristic of study population
Total n 108
Male Gender (%) 90 (83)
Age at enrolment (years) [median (IQR)] 40 (21-75)
Age at enrolment
10-31
31-40
41-50
>50
24 (22)
30 (28)
27 (25)
27 (25)
CD4 count at enrolment (cells/ l) [median (IQR)]
<200
200-350
>350
26 (24)
36 (33)
46 (43)
Viral load at enrolment copies/mL [median (IQR)] 66.328 (19-4.858.589)
Values are n (%) unless otherwise stated; QR: interquartile rang.
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Among indicators with poorer outcomes, undetecta-
ble viral load seems the most important. The aim of ART
is to suppress viral replication rapidly and durably to get
a figure lower than 50 copies/ml. This goal has been
shown to prevent the mutation selection21,22 and to in-
crease virological response23.
In our study 74.1% of patients had undetectable viral
load. Such a low number can be explained because recent
infections or breakthrough viral load was not specified.
The relationship between resistance mutations and vi-
rologic failure has been evidenced with the monitoring
of the viral load. 
Current treatments have dramatically reduced the fre-
quency of treatment failure and virological failure rates in
first-line treatment were between 20-40%24,25.
Prospective randomized studies have shown that the
use of genotypic resistances tests in patients with virolo-
gical failure was associated with a better virological con-
trol at three and six months and a better vital prognosis26.
In our study, patients with virological failure was low
(limited) and a percentage value may not be indicative of
global relevance.
Therapeutic compliance is one of the variables that
best predicts virological response. Non-adherence increa-
ses the risk of acquiring resistances and morbidity and
mortality associated with HIV infection5.
Treatment adherence should be assessed regularly be-
cause this allows estimated the patient's ability to get in-
volved in their own health care and in their disease.
Our study has several limitations. Firstly, we have work
in a follow up cohort from a limited geographical area,
Andalusia. We think that this cohort was representative
because in this area, the national guidelines were follo-
wed. Secondly, all pharmacotherapeutic monitoring in-
dicators have not been selected. Some aspects such as
the establishment of the first treatment or first medical
visit go beyond the pharmaceutical field. 
Our new lines of research will focus on determining
persistence of therapy in this cohort and on the analysis
of time series data.
In conclusion, in our multicentre cohort, quality care
follow up indicators (GESIDA) for adult patients living
with HIV infection were fulfilled in their vast majority. The
worst accomplished indicators such as undetectable viral
load at 48 weeks, evaluation of adherence and study of
resistance in the virologic failure must be study to exa-
mine the possible improvement points. 
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